The estimated Net Worth of David C Marek is at least $42.2 Milión dollars as of 18 January 2023. Mr. Marek owns over 8,037 units of Axsome Therapeutics Inc stock worth over $38,014,037 and over the last 5 years he sold AXSM stock worth over $1,189,802. In addition, he makes $2,969,930 as Chief Commercial Officer at Axsome Therapeutics Inc.
Sign up
Mr. Marek AXSM stock SEC Form 4 insiders trading
David has made over 5 trades of the Axsome Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 8,037 units of AXSM stock worth $216,115 on 18 January 2023.
The largest trade he's ever made was selling 24,594 units of Axsome Therapeutics Inc stock on 19 April 2022 worth over $257,007. On average, David trades about 6,236 units every 30 days since 2019. As of 18 January 2023 he still owns at least 417,599 units of Axsome Therapeutics Inc stock.
You can see the complete history of Mr. Marek stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Marek biography
David C. Marek serves as Chief Commercial Officer of the Company. Prior to joining Axsome, from June 2017 to August 2019, Mr. Marek held the position of Vice President, and General Manager of Amgen’s Neuroscience business unit. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig™ for migraine prevention. Prior to heading the Neuroscience business unit, he was Vice President of Marketing of Amgen’s U.S. Inflammation and Nephrology business from June 2015 to June 2017. Before Amgen, Mr. Marek served as Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD. Prior to that position, Mr. Marek was the Managing Director of Saatchi & Saatchi Healthcare Advertising. Mr. Marek began his career at Eli Lilly and Company, followed by AstraZeneca, where he served in a variety of marketing and sales roles of increasing responsibility. He earned his Bachelor of Arts degree in Business Administration from Washington State University.
What is the salary of David Marek?
As the Chief Commercial Officer of Axsome Therapeutics Inc, the total compensation of David Marek at Axsome Therapeutics Inc is $2,969,930. There are 1 executives at Axsome Therapeutics Inc getting paid more, with Herriot Tabuteau having the highest compensation of $4,715,750.
How old is David Marek?
David Marek is 55, he's been the Chief Commercial Officer of Axsome Therapeutics Inc since 2019. There are no older and 13 younger executives at Axsome Therapeutics Inc.
What's David Marek's mailing address?
David's mailing address filed with the SEC is C/O MYOVANT SCIENCES, INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE, CA, 94005.
Insiders trading at Axsome Therapeutics Inc
Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony a Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.
What does Axsome Therapeutics Inc do?
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
What does Axsome Therapeutics Inc's logo look like?
Complete history of Mr. Marek stock trades at Axsome Therapeutics Inc a Myovant Sciences Ltd
Axsome Therapeutics Inc executives and stock owners
Axsome Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Herriot Tabuteau,
Chairman of the Board, President, Chief Executive Officer, Founder -
David Marek,
Chief Commercial Officer -
Nick Pizzie,
Chief Financial Officer -
Dr. Herriot Tabuteau M.D.,
Founder, Chairman, CEO & Pres -
Mark L. Jacobson,
COO & Sec. -
Nick Pizzie CPA, M.B.A.,
Chief Financial Officer -
Roger Jeffs,
Lead Independent Director -
Mark Saad,
Independent Director -
Mark Coleman,
Independent Director -
Amanda Jones,
Senior Vice President - Clinical Research -
Cedric O'Gorman,
Senior Vice President - Clinical Development and Medical Affairs -
Mark Jacobson,
Chief Operating Officer -
Joseph Debrah-Afful CPA, M.B.A.,
Director of Fin. -
Kevin Laliberte Pharm.D.,
Exec. VP of Product Strategy -
Lori Englebert M.B.A.,
Sr. VP of Commercial & Bus. Devel. -
Dr. Amanda Jones Pharm.D.,
Sr. VP of Clinical Devel. -
Constance Ames,
Vice President, Finance -
Myrtle S Potter,
Director -
Randall Kaye,
Chief Medical Officer -
Hunter R. Murdock,
General Counsel -
John Golubieski,
Chief Financial Officer -
Susan Mahony,